- In February 2022, Asklepios BioPharmaceutical, Inc., a subsidiary of Bayer AG, announced that the European Commission (EC) granted orphan drug designation to AB-1003, also referred to as LION-101, for treating limb girdle muscular dystrophy. This designation highlights the drug's potential in addressing the needs of patients with this rare condition. Securing orphan drug status can facilitate expedited development and regulatory processes, paving the way for earlier access to much-needed therapies
- In September 2024, Atamyo Therapeutics has collaborated with the Dion Foundation for Children with Rare Diseases to initiate a clinical trial in the U.S. for ATA-200, a promising gene therapy aimed at treating limb girdle muscular dystrophy type 2C/R5 (LGMD2C/R5). This partnership highlights a commitment to advancing innovative therapies for patients affected by this rare condition. The trial's expansion into the U.S. signifies a crucial step in exploring the potential of ATA-200 as a treatment option for individuals suffering from LGMD2C/R5
Frequently Asked Questions
The market is segmented based on Segmentation, By Symptoms (Weakness of the Proximal Muscles of the Hip and Shoulder, Additional Abnormalities, Weakening of the Heart Muscle, and Others), Treatment (Surgery, Therapy, and Others), Mode of Administration (Injectable, Oral, and Others), End User (Hospitals, Homecare, Specialty Clinics, and Others) – Industry Trends and Forecast to 2031
.
The Global Limb Gridle Muscular Dystrophy Market size was valued at USD 1.30 USD Billion in 2023.
The Global Limb Gridle Muscular Dystrophy Market is projected to grow at a CAGR of 4.7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
